TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05876143

Intervention type: DEVICE
Intervention: Unicompartmental knee arthroplasty
Description: Knee joint could be subject to natural or pathological wear or shocks (primary or secondary evolutive or traumatic osteoarthritis) which cause pain and reduced mobility of the knee.~When only one lateral or medial compartment of the femoro-tibial knee joint is affected, the treatment of unicompartmental femoro-tibial osteoarthritis of the knee is generally carried out by the implantation of a so-called unicondylar knee prosthesis (UKP), in order to reduce pain and improve joint mobility of the knee compared to the preoperative state.

Intervention type: DEVICE
Intervention: Unicompartmental knee arthroplasty
Description: Knee joint could be subject to natural or pathological wear or shocks (primary or secondary evolutive or traumatic osteoarthritis) which cause pain and reduced mobility of the knee.~When only one lateral or medial compartment of the femoro-tibial knee joint is affected, the treatment of unicompartmental femoro-tibial osteoarthritis of the knee is generally carried out by the implantation of a so-called unicondylar knee prosthesis (UKP), in order to reduce pain and improve joint mobility of the knee compared to the preoperative state.
Study: NCT05730504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app-based self-guided interventions
Description: self-guided, app-based mobile psychological interventions based on CBT, meditation, mindfulness, journaling, and audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation
Study: NCT06142370

Intervention type: OTHER
Group type: OTHER
Intervention: Descriptive
Description: The patients will be asked by the recruiting physicians to perform a clinical examination looking for the LCV, which will take a total of five seconds. This is a self-test and not part of a regular clinical examination
Study: NCT06359743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lamborum versus superior hypogatric
Description: Ultrasound Guided Quadratus Lumborum Block versus Laparoscopic Superior Hypogastric Plexus Block for Postoperative Analgesia after Laparoscopic Hysterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lamborum versus superior hypogatric
Description: Ultrasound Guided Quadratus Lumborum Block versus Laparoscopic Superior Hypogastric Plexus Block for Postoperative Analgesia after Laparoscopic Hysterectomy
Study: NCT06441110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab in Combination with Bacillus Calmette-Guérin
Description: Postoperative immediate instillation of epirubicin (50mg) is administered. Postoperatively, 200mg of tislelizumab injection is given intravenously every 3 weeks, with each 21-day period constituting one cycle. The medication is administered on day 1 of each cycle, continuing for one year. Eligible patients for the single-arm group (N = 76) begin BCG instillation after 2 weeks, with a dosage of 120mg per instillation, totaling 19 instillations: this starts with a 6-week induction phase of weekly BCG instillations, followed by BCG instillations every 2 weeks for three consecutive times; thereafter, maintenance instillation therapy commences, involving monthly BCG instillations for a total of ten times.
Study: NCT05729425

Intervention type: DEVICE
Intervention: Ultrasound Microvessel Imaging
Description: Undergo microvessel ultrasound imaging
Study: NCT05364983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvene IOL
Description: Cataract extraction and implantation of a posterior chamber IOL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis® Monofocal (ZCB00, PCB00 or DCB00)
Description: Cataract extraction and implantation of a posterior chamber IOL
Study: NCT05226559

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Physical therapy approach plus usual care
Description: HVLA spinal manipulation, mobilization, soft tissue treatment, therapeutic exercise, education, plus standard pharmacological treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Standard pharmacological treatment alone.
Study: NCT06365515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa administration
Description: To boost dopamine levels 150mg/37.5 mg L-DOPA/benserazide will be administered in line with recent studies (Kroemer et al., 2019). Maximum plasma concentration of Madopar occur \~60 minutes after drug administration. Participants will start the Effort Allocation Task 45 minutes after Levodopa administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa administration
Description: To boost dopamine levels 150mg/37.5 mg L-DOPA/benserazide will be administered in line with recent studies (Kroemer et al., 2019). Maximum plasma concentration of Madopar occur \~60 minutes after drug administration. Participants will start the Effort Allocation Task 45 minutes after Levodopa administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa administration
Description: To boost dopamine levels 150mg/37.5 mg L-DOPA/benserazide will be administered in line with recent studies (Kroemer et al., 2019). Maximum plasma concentration of Madopar occur \~60 minutes after drug administration. Participants will start the Effort Allocation Task 45 minutes after Levodopa administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo administration
Description: Placebo tablets will be administered as the placebo-controlled condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo administration
Description: Placebo tablets will be administered as the placebo-controlled condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo administration
Description: Placebo tablets will be administered as the placebo-controlled condition.
Study: NCT05876143

Intervention type: DEVICE
Intervention: Unicompartmental knee arthroplasty
Description: Knee joint could be subject to natural or pathological wear or shocks (primary or secondary evolutive or traumatic osteoarthritis) which cause pain and reduced mobility of the knee.~When only one lateral or medial compartment of the femoro-tibial knee joint is affected, the treatment of unicompartmental femoro-tibial osteoarthritis of the knee is generally carried out by the implantation of a so-called unicondylar knee prosthesis (UKP), in order to reduce pain and improve joint mobility of the knee compared to the preoperative state.

Intervention type: DEVICE
Intervention: Unicompartmental knee arthroplasty
Description: Knee joint could be subject to natural or pathological wear or shocks (primary or secondary evolutive or traumatic osteoarthritis) which cause pain and reduced mobility of the knee.~When only one lateral or medial compartment of the femoro-tibial knee joint is affected, the treatment of unicompartmental femoro-tibial osteoarthritis of the knee is generally carried out by the implantation of a so-called unicondylar knee prosthesis (UKP), in order to reduce pain and improve joint mobility of the knee compared to the preoperative state.

Intervention type: DEVICE
Intervention: Unicompartmental knee arthroplasty
Description: Knee joint could be subject to natural or pathological wear or shocks (primary or secondary evolutive or traumatic osteoarthritis) which cause pain and reduced mobility of the knee.~When only one lateral or medial compartment of the femoro-tibial knee joint is affected, the treatment of unicompartmental femoro-tibial osteoarthritis of the knee is generally carried out by the implantation of a so-called unicondylar knee prosthesis (UKP), in order to reduce pain and improve joint mobility of the knee compared to the preoperative state.
Study: NCT06521801

Intervention type: OTHER
Intervention: Observation
Description: Observation
Study: NCT06294821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-Aminopyridine
Description: Subjects will receive either the active study drug (4-aminopyridine) or placebo to determine the effects of 4AP on carpal tunnel syndrome

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive either the active study drug (4-aminopyridine) or placebo to determine the effects of 4AP on carpal tunnel syndrome
Study: NCT05880212

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual physiotherapy care
Description: In Phase 1, physiotherapists will provide treatment for participants with chronic low back pain in accordance with their current standard physiotherapy practice. Physiotherapists will be free to choose the treatment approach they wish to.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized (STOPS) physiotherapy
Description: In Phase 3, participants will receive individualized physiotherapy in accordance with the Specific Treatment of Problems of the Spine (STOPS) approach modified for chronic low back pain. Treatment will be individualized on the basis of biopsychosocial assessment findings including dominant pain type (nociceptive, neuropathic or nociplastic), pathoanatomical subgroups (if any), and other barriers to recovery (eg. inflammation, depression, anxiety, stress, catastrophising, pain self-efficacy, and unhelpful motor control strategies). Available treatment strategies will include individualized education/advice, exercise, manual therapy, activity modification/facilitation, goal setting, motor control optimisation, cognitive-behavioural strategies, inflammation management, pain management strategies, sleep management, work management, and relaxation approaches.
Study: NCT05378828

Intervention type: DEVICE
Group type: OTHER
Intervention: Using anti-collision Sensors on electric wheelchairs
Description: use of anti-collision sensors on the electric wheelchair during 3 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Use of an electric wheelchair without sensors
Description: Use of an electric wheelchair without sensors for 3 weeks before using anti-collision sensors then during 3 weeks after using the anti-collision sensors.
Study: NCT05615402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone-specific strength training
Description: Muscular strength and rate of force development (RFD) will be assessed in the key exercises of the intervention protocol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition optimalisation
Description: Dietary supplement of protein, vitamin D and Calcium 3x/w Dietary counselling based on individual dietary records

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition optimalisation
Description: Dietary supplement of protein, vitamin D and Calcium 3x/w Dietary counselling based on individual dietary records
Study: NCT04861584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin
Description: 4 cycle neoadjuvant therapy and radical cystectomy
Study: NCT06411834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision navigation tool
Description: An electronic, interactive form that guides patients through the major factors that influence their decision-making in thyroid cancer
Study: NCT05035004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post exercise hot water immersion
Description: Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max), followed by a 10-minute transfer period and then 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max).
Study: NCT05907330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU104
Description: CU104 will administer the study drug once a day after a meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will administer the study drug once a day after a meal
Study: NCT06218264

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of an amino acid supplement
Description: Oral intake of a supplement containing amino acids

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of an amino acid supplement
Description: Oral intake of a supplement containing amino acids
Study: NCT05344651

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery/implantation
Description: The glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal quadrant of the eye. The tube is positioned in the anterior chamber.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgery/implantation
Description: The glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal quadrant of the eye. The tube is positioned in the anterior chamber.
Study: NCT05880836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen
Description: nebulized delivery of bronchodilator via in-line drug delivery maintaining high-flow nasal cannula oxygen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen
Description: nebulized delivery of bronchodilator via in-line drug delivery maintaining high-flow nasal cannula oxygen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard jet nebulization (SJN) with face mask
Description: standard jet nebulization delivery of bronchodilator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard jet nebulization (SJN) with face mask
Description: standard jet nebulization delivery of bronchodilator
Study: NCT06409650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826 dosed at 2.5mg
Description: 2.5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826 dosed at 2.5mg
Description: 2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826 dosed at 5 mg
Description: 5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
Study: NCT05035004

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hot water immersion
Description: Participants will complete 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C), followed by a 10-minute transfer period and then an additional 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
Study: NCT05626855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apitegromab
Description: Apitegromab (SRK-015) is an investigational, fully human immunoglobulin G4 monoclonal antibody that specifically binds to human proforms (i.e., inactive precursor forms) of myostatin, pro- and latent- myostatin, with high affinity, inhibiting activation of myostatin, a negative regulator of muscle growth and strength.
Study: NCT03875339

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Navigator Guidance
Description: Use of a dedicated Navigator to determine if follow-up and compliance rates can be improved for those infants initially demonstrating an abnormal hearing result.
Study: NCT05822661

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black Seed Oil
Description: Dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules same odor, color and size as the drug but without the active ingredient
Study: NCT06409650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826 dosed at 5 mg
Description: 5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to KX-826
Description: Placebo applied topically to scalp once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to KX-826
Description: Placebo applied topically to scalp twice daily for 24 weeks
Study: NCT06376292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Injection of Thiotepa+Radiation+Systemic Treatment of Primary Diseases
Description: Participants will receive a comprehensive treatment plan consisting mainly of whole brain 30Gy/10F radiotherapy combined with intrathecal injection of Thiotepa. The injection was administered by qualified individuals (certified personnel in the radiotherapy department of our hospital) twice a week for a total of 4 weeks. Thiotepa was injected 10mg each time, mixed with cerebrospinal fluid, and then injected slowly for 5-10 minutes.
Study: NCT05357313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: Exposure to 10,000lux bright light for 30minutes a day for six weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactive negative ion generator
Description: Exposure to an inactive negative ion generator for 30 minutes a day for six weeks
Study: NCT05454228

Intervention type: BEHAVIORAL
Intervention: postoperative delirium
Description: Postoperative delirium (POD) occurs within 1 week after surgery in patients, with obvious time characteristics, mainly occurring within 1-3 days after surgery. Postoperative delirium has adverse effects on the short and long term prognosis of patients. Patients with delirium have an increased risk of postoperative complications, perioperative death, longer hospital stay and increased medical costs during hospitalization.

Intervention type: BEHAVIORAL
Intervention: postoperative delirium
Description: Postoperative delirium (POD) occurs within 1 week after surgery in patients, with obvious time characteristics, mainly occurring within 1-3 days after surgery. Postoperative delirium has adverse effects on the short and long term prognosis of patients. Patients with delirium have an increased risk of postoperative complications, perioperative death, longer hospital stay and increased medical costs during hospitalization.
Study: NCT04275531

Intervention type: DRUG
Intervention: Anesthesia Agent
Description: various anesthetic agents used in both general and regional anesthesia

Intervention type: DRUG
Intervention: Anesthesia Agent
Description: various anesthetic agents used in both general and regional anesthesia

Intervention type: DRUG
Intervention: Anesthesia Agent
Description: various anesthetic agents used in both general and regional anesthesia

Intervention type: DRUG
Intervention: Anesthesia Agent
Description: various anesthetic agents used in both general and regional anesthesia
Study: NCT05070702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-1500
Description: Hard Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-1500
Description: Hard Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hard Capsule
Study: NCT05383859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: 1. Dietary and/ or physical activity: face to face plus written material (at baseline)~2. 3 months later: motivational phone call.
Study: NCT05070702

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hard Capsule
Study: NCT06489834

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Drumming
Description: Weekly group drumming for 8 weeks
Study: NCT06363253

Intervention type: OTHER
Intervention: No specific intervention
Description: Patient will undergo their routine clinical treatment for their related clinical condition (eg. anti-obesity or bariatric intervention for obese group; muscle strengthening interventions or necessary treatment for their concomitant medical condition for the sarcopenia group).~Follow-up testing will include repeat assessment of the subjects metagenome and metabolome over time, and after intervention~Control subjects will have no interventions performed as well.

Intervention type: OTHER
Intervention: No specific intervention
Description: Patient will undergo their routine clinical treatment for their related clinical condition (eg. anti-obesity or bariatric intervention for obese group; muscle strengthening interventions or necessary treatment for their concomitant medical condition for the sarcopenia group).~Follow-up testing will include repeat assessment of the subjects metagenome and metabolome over time, and after intervention~Control subjects will have no interventions performed as well.
Study: NCT04782817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommendation for high flow nasal cannula oxygen therapy order set
Description: Participants will be assigned post extubation physician order set which recommends the administration of oxygen therapy via HFNC. HFNC is a heated and humidified system that allows prescribed fraction of inspired oxygen (FIO2) levels to be delivered at very high flow rates.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provider choice standard care order set
Description: Participants will receive order set with provider choice of standard care therapy.
Study: NCT05493254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation e-visit
Description: electronic visits (e-visits) for smoking cessation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
Study: NCT06238869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavioral Therapy
Description: CCBT (Computerized Cognitive Behavioral Therapy) is a unique approach to improving mental well-being. It utilizes computer-based cognitive and behavioral techniques to induce relaxation and regulate emotional responses by targeting specific brain regions. CCBT offers interactive and personalized interventions, empowering individuals to address mental health challenges like depression and anxiety. Its convenience and accessibility through digital platforms make it a practical choice for enhancing emotional well-being.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Health education focuses on providing insights into adolescent mental health, offering practical coping strategies and behavior patterns. It emphasizes the crucial link between parental guidance and the well-being of adolescents. By fostering healthier psychological interactions, it cultivates an environment supportive of adolescent mental health, strengthens family support, and promotes comprehensive development in physical, mental, and cognitive aspects.